Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma

Gynecologic Oncology

Volumn 103, Issue 2, 2006, Pages 684-687

  Vaidya, Ami P ^a   Horowitz, Neil S ^a   Oliva, Esther ^a   Halpern, Elkan F ^a   Duska, Linda R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Carcinosarcoma; Endometrial; Malignant mixed mullerian tumors

Indexed keywords

CARBOPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; PACLITAXEL;

AGE DISTRIBUTION; ARTICLE; CANCER REGISTRY; CANCER STAGING; ENDOMETRIUM CARCINOMA; HUMAN; LOG RANK TEST; MIXED MULLERIAN TUMOR; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; UTERUS CARCINOMA;

CARCINOMA, ENDOMETRIOID; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIXED TUMOR, MULLERIAN; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; UTERINE NEOPLASMS;

EID: 33750160521     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.05.009     Document Type: Article

References (13)

1. Silverberg S.G., Major F.J., Blessing J.A., Fetter B., Askin F.B., Liao S.Y., et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int. J. Gynecol. Pathol. 9 1 (1990) 1-19
2. Zelmanowicz A., Hildesheim A., Sherman M.E., Sturgeon S.R., Kurman R.J., Barrett R.J., et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol. Oncol. 69 3 (1998) 253-257
3. McCluggage W.G. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int. J. Gynecol. Cancer 12 6 (2002) 687-690
4. Duska L.R., Berkowitz R., Matulonis U., Muto M., Goodman A., McIntyre J.F., et al. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol. Oncol. 96 1 (2005) 198-203
5. Grice J., Ek M., Greer B., Koh W.J., Muntz H.G., Cain J., et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol. Oncol. 69 1 (1998) 69-73
6. Goff B.A., Rice L.W., Fleischhacker D., Muntz H.G., Falkenberry S.S., Nikrui N., et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence. Gynecol. Oncol. 50 1 (1993) 105-109
7. Amant F., Cadron I., Fuso L., Berteloot P., de Jonge E., Jacomen G., et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol. Oncol. 98 2 (2005) 274-280
8. Mark R.J., Poen J., Tran L.M., Fu Y.S., Heaps J., and Parker R.G. Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies. Am. J. Clin. Oncol. 19 1 (1996) 59-64
9. Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler J., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 24 1 (2006) 36-44
10. Duska L.R., Garrett A., Eltabbakh G.H., Oliva E., Penson R., and Fuller A.F. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol. Oncol. 85 3 (2002) 459-463
11. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. 22 11 (2004) 2159-2166
12. Hoskins P.J., Swenerton K.D., Pike J.A., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J. Clin. Oncol. 19 (2001) 4048-4053
13. Homesley H.D., Filiaci V.L., Bitterman P., et al. Phase III trial of ifosfamide versus ifosphamide plus paclitaxel as first-line treatment of advanced or recurrent uterine carcinosarcoma (mixed mesodermal tumors): a Gynecologic Oncology Group study. Gynecol. Oncol. 101 (2006) S31 (suppl.)